Molecular modeling-guided optimization of acetylcholinesterase reactivators: A proof for reactivation of covalently inhibited targets.


Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
05 Apr 2021
Historique:
received: 15 10 2020
revised: 23 12 2020
accepted: 03 02 2021
pubmed: 22 2 2021
medline: 7 4 2021
entrez: 21 2 2021
Statut: ppublish

Résumé

Covalent drugs have been intensively studied in some very important fields such as anti-tumor and anti-virus, including the currently global-spread SARS-CoV-2. However, these drugs may interact with a variety of biological macromolecules and cause serious toxicology, so how to reactivate the inhibited targets seems to be imperative in the near future. Organophosphate was an extreme example, which could form a covalent bound easily with acetylcholinesterase and irreversibly inhibited the enzyme, causing high toxicology. Some nucleophilic oxime reactivators for organophosphate poisoned acetylcholinesterase had been developed, but the reactivation process was still less understanding. Herein, we proposed there should be a pre-reactivated pose during the reactivating process and compounds whose binding pose was easy to transfer to the pre-reactivated pose might be efficient reactivators. Then we refined the previous reactivators based on the molecular dynamic simulation results, the resulting compounds L7R3 and L7R5 were proven as much more efficient reactivators for organophosphate inhibited acetylcholinesterase than currently used oximes. This work might provide some insights for constructing reactivators of covalently inhibited targets by using computational methods.

Identifiants

pubmed: 33611189
pii: S0223-5234(21)00135-5
doi: 10.1016/j.ejmech.2021.113286
pmc: PMC7877871
pii:
doi:

Substances chimiques

Cholinesterase Inhibitors 0
Cholinesterase Reactivators 0
Organophosphorus Compounds 0
Acetylcholinesterase EC 3.1.1.7

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113286

Informations de copyright

Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Eur J Med Chem. 2014 May 6;78:455-67
pubmed: 24704618
Adv Clin Chem. 2004;38:151-216
pubmed: 15521192
Chembiochem. 2017 Apr 4;18(7):666-675
pubmed: 28106328
Chem Biol Interact. 2005 Dec 15;157-158:181-9
pubmed: 16256966
Chem Biol Interact. 2010 Sep 6;187(1-3):207-14
pubmed: 20223229
Chem Commun (Camb). 2014 Apr 18;50(30):3947-50
pubmed: 24599312
Drug Metab Dispos. 1988 Jul-Aug;16(4):515-20
pubmed: 2903016
Biochem Pharmacol. 2004 Dec 1;68(11):2237-48
pubmed: 15498514
Toxicol Appl Pharmacol. 1982 Jun 15;64(1):140-6
pubmed: 7112578
Biochem Pharmacol. 1961 Jul;7:88-95
pubmed: 13726518
Bioorg Med Chem. 2017 Aug 15;25(16):4497-4505
pubmed: 28684009
Acc Chem Res. 2012 May 15;45(5):756-66
pubmed: 22360473
Pharmacol Ther. 1993;58(1):51-66
pubmed: 8415873
Bioorg Med Chem Lett. 2014 Apr 1;24(7):1711-4
pubmed: 24630558
Curr Med Chem. 2009;16(17):2177-88
pubmed: 19519385
Proc Natl Acad Sci U S A. 2016 May 17;113(20):5514-9
pubmed: 27140636
Science. 2020 Jun 19;368(6497):1331-1335
pubmed: 32321856
Ann Emerg Med. 1992 Jul;21(7):865-71
pubmed: 1610046
Toxicol Lett. 2009 Oct 28;190(2):107-15
pubmed: 19651196
J Mol Neurosci. 2010 Jan;40(1-2):63-9
pubmed: 19680820
J Med Chem. 2011 May 12;54(9):3319-30
pubmed: 21438612
J Med Chem. 2012 Jan 12;55(1):465-74
pubmed: 22206546
Br J Pharmacol Chemother. 1958 Dec;13(4):399-403
pubmed: 13618543
Nat Rev Drug Discov. 2011 Apr;10(4):307-17
pubmed: 21455239
J Med Chem. 2012 Dec 13;55(23):10791-5
pubmed: 23148598
Curr Med Chem. 2008;15(8):743-53
pubmed: 18393843
Lancet. 2002 Oct 12;360(9340):1163-7
pubmed: 12387969
World Health Stat Q. 1990;43(3):139-44
pubmed: 2238694
Chem Commun (Camb). 2011 May 14;47(18):5295-7
pubmed: 21451868
Chem Biol Interact. 2011 Nov 15;194(2-3):91-6
pubmed: 21930118
Chem Res Toxicol. 2018 Dec 17;31(12):1405-1417
pubmed: 30462502
Chem Biol Interact. 2013 Mar 25;203(1):81-4
pubmed: 23111374
Eur J Pharmacol. 2006 Dec 28;553(1-3):10-7
pubmed: 17109842
J Mol Biol. 2000 Feb 18;296(2):713-35
pubmed: 10669619
Chem Rev. 2019 Aug 28;119(16):9478-9508
pubmed: 31244000
J Toxicol Clin Toxicol. 2002;40(6):803-16
pubmed: 12475193
Lancet. 2008 Feb 16;371(9612):597-607
pubmed: 17706760
Bioorg Chem. 2018 Dec;81:681-688
pubmed: 30265992
Drug Discov Today. 2015 Sep;20(9):1061-73
pubmed: 26002380

Auteurs

Zhao Wei (Z)

Department of Medicinal Chemistry, School of Pharmacy, Fourth Military Medical University, Xi'an, 300071, China. Electronic address: weizhaobruce@163.com.

Jie Yang (J)

Department of Medicinal Chemistry, School of Pharmacy, Third Military Medical University, Chongqing, 400038, China.

Yanqin Liu (Y)

Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing, 100850, China.

Huifang Nie (H)

Department of Medicinal Chemistry, School of Pharmacy, Fourth Military Medical University, Xi'an, 300071, China.

Lin Yao (L)

Department of Medicinal Chemistry, School of Pharmacy, Fourth Military Medical University, Xi'an, 300071, China.

Jun Yang (J)

Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing, 100850, China.

Lei Guo (L)

Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing, 100850, China.

Zhibing Zheng (Z)

Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing, 100850, China. Electronic address: zzbcaptain@aliyun.com.

Qin Ouyang (Q)

Department of Medicinal Chemistry, School of Pharmacy, Third Military Medical University, Chongqing, 400038, China. Electronic address: ouyangq@tmmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH